RCKT
Rocket Pharmaceuticals, Inc. NASDAQ Listed Feb 18, 2015$3.73
Mkt Cap $407.0M
52w Low $2.19
29.6% of range
52w High $7.39
50d MA $4.09
200d MA $3.56
P/E (TTM)
-1.8x
EV/EBITDA
-1.6x
P/B
1.4x
Debt/Equity
0.1x
ROE
-80.5%
P/FCF
-2.0x
RSI (14)
—
ATR (14)
—
Beta
0.57
50d MA
$4.09
200d MA
$3.56
Avg Volume
3.4M
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
9 Cedarbrook Drive · Cranbury, NJ 08512 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -0.41 | -0.42 | -2.4% | 3.67 | +2.7% | -1.1% | — | — | — | — | — |
| Feb 26, 2026 | AMC | -0.42 | -0.38 | +9.5% | 4.53 | +1.3% | +10.6% | +9.7% | +6.0% | +6.4% | +2.4% | — |
| Nov 6, 2025 | AMC | -0.48 | -0.45 | +6.2% | 3.23 | +0.9% | -1.9% | -2.5% | +0.9% | +2.2% | -1.9% | — |
| Aug 7, 2025 | AMC | -0.57 | -0.59 | -3.5% | 3.09 | +1.0% | -7.4% | -5.5% | -5.8% | +0.0% | -1.9% | — |
| May 8, 2025 | AMC | -0.59 | -0.56 | +5.1% | 7.04 | -0.4% | -0.7% | -0.6% | -6.0% | -13.9% | -4.4% | — |
| Feb 27, 2025 | AMC | -0.68 | -0.62 | +8.8% | 9.40 | +1.6% | +0.5% | -6.5% | -7.9% | -2.0% | -4.4% | — |
| Nov 7, 2024 | AMC | -0.78 | -0.71 | +9.0% | 17.25 | +0.2% | +1.2% | -2.3% | -7.1% | -9.2% | -14.1% | — |
| Aug 5, 2024 | AMC | -0.74 | -0.74 | +0.0% | 19.96 | +4.5% | +0.9% | -5.3% | -4.2% | -4.6% | -5.1% | — |
| May 6, 2024 | AMC | -0.69 | -0.66 | +4.3% | 23.20 | +0.8% | +0.7% | -0.9% | +0.6% | -2.1% | -0.5% | — |
| Feb 26, 2024 | AMC | -0.80 | -0.64 | +20.0% | 29.79 | +5.0% | +3.2% | -2.6% | -1.6% | +2.5% | -3.6% | — |
| Nov 6, 2023 | AMC | -0.82 | -0.75 | +8.5% | 19.93 | +1.6% | +2.7% | -1.8% | -8.8% | -6.9% | -2.1% | — |
| Aug 10, 2023 | AMC | -0.80 | -0.82 | -2.5% | 16.78 | -1.2% | -1.5% | -0.4% | -3.2% | -6.0% | -8.6% | — |
| May 4, 2023 | AMC | -0.86 | -0.73 | +15.1% | 18.69 | +1.7% | +12.4% | +14.3% | +10.6% | +12.0% | +8.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30 | BofA Securities | Maintains | Buy → Buy | — | $3.77 | $3.75 | -0.5% | -8.5% | -5.0% | -4.0% | -5.8% | -8.2% |
| Mar 27 | Chardan Capital | Maintains | Buy → Buy | — | $4.69 | $4.71 | +0.4% | -19.6% | -26.4% | -23.7% | -22.8% | -24.3% |
| Mar 2 | Goldman Sachs | Maintains | Sell → Sell | — | $5.01 | $4.95 | -1.2% | -0.8% | -4.2% | -3.8% | -7.4% | -12.0% |
| Feb 27 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $4.53 | $4.59 | +1.3% | +10.6% | +9.7% | +6.0% | +6.4% | +2.4% |
| Nov 18 | BofA Securities | Maintains | Buy → Buy | — | $3.04 | $2.90 | -4.6% | -3.3% | -5.3% | -6.6% | -3.6% | -0.3% |
| Nov 18 | JP Morgan | Downgrade | Overweight → Underweight | — | $3.04 | $2.90 | -4.6% | -3.3% | -5.3% | -6.6% | -3.6% | -0.3% |
| Oct 14 | Chardan Capital | Maintains | Buy → Buy | — | $3.47 | $3.92 | +13.0% | +23.1% | +22.2% | +15.3% | +6.9% | +15.3% |
| Oct 3 | Leerink Partners | Maintains | Market Perform → Market Perform | — | $3.21 | $3.19 | -0.6% | -1.9% | -0.9% | -2.2% | +5.6% | +14.3% |
| Aug 20 | BofA Securities | Upgrade | Neutral → Buy | — | $2.91 | $3.83 | +31.6% | +28.9% | +28.2% | +25.1% | +21.6% | +16.5% |
| Aug 20 | Chardan Capital | Maintains | Buy → Buy | — | $2.91 | $3.83 | +31.6% | +28.9% | +28.2% | +25.1% | +21.6% | +16.5% |
| Aug 11 | Chardan Capital | Maintains | Buy → Buy | — | $2.86 | $2.90 | +1.4% | +2.1% | +1.7% | +8.0% | +5.9% | +6.6% |
| Aug 8 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.09 | $3.12 | +1.0% | -7.4% | -5.5% | -5.8% | +0.0% | -1.9% |
| Jul 25 | BofA Securities | Downgrade | Buy → Neutral | — | $3.21 | $3.11 | -3.1% | -2.2% | -3.1% | -6.2% | -2.2% | -5.0% |
| Jul 25 | Canaccord Genuity | Maintains | Buy → Buy | — | $3.21 | $3.11 | -3.1% | -2.2% | -3.1% | -6.2% | -2.2% | -5.0% |
| Jul 24 | Needham | Maintains | Hold → Hold | — | $3.36 | $3.32 | -1.2% | -4.5% | -6.5% | -7.4% | -10.4% | -6.5% |
| Jul 24 | Chardan Capital | Maintains | Buy → Buy | — | $3.36 | $3.32 | -1.2% | -4.5% | -6.5% | -7.4% | -10.4% | -6.5% |
| Jun 17 | UBS | Maintains | Buy → Buy | — | $2.88 | $2.87 | -0.3% | -5.6% | -1.7% | -6.2% | -8.7% | -3.8% |
| Jun 3 | Canaccord Genuity | Maintains | Buy → Buy | — | $2.77 | $2.76 | -0.4% | +6.9% | +5.4% | +0.0% | +10.8% | +9.0% |
| May 28 | BMO Capital | Maintains | Outperform → Outperform | — | $2.33 | $2.38 | +2.1% | +6.4% | +12.4% | +7.7% | +18.9% | +27.0% |
| May 28 | BofA Securities | Maintains | Buy → Buy | — | $2.33 | $2.38 | +2.1% | +6.4% | +12.4% | +7.7% | +18.9% | +27.0% |
| May 28 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $2.33 | $2.38 | +2.1% | +6.4% | +12.4% | +7.7% | +18.9% | +27.0% |
| May 28 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $2.33 | $2.38 | +2.1% | +6.4% | +12.4% | +7.7% | +18.9% | +27.0% |
| May 28 | JP Morgan | Downgrade | Overweight → Neutral | — | $2.33 | $2.38 | +2.1% | +6.4% | +12.4% | +7.7% | +18.9% | +27.0% |
| May 28 | Jefferies | Downgrade | Buy → Hold | — | $2.33 | $2.38 | +2.1% | +6.4% | +12.4% | +7.7% | +18.9% | +27.0% |
| May 28 | Chardan Capital | Maintains | Buy → Buy | — | $2.33 | $2.38 | +2.1% | +6.4% | +12.4% | +7.7% | +18.9% | +27.0% |
| May 27 | BofA Securities | Maintains | Buy → Buy | — | $6.27 | $2.30 | -63.3% | -62.8% | -60.4% | -58.2% | -60.0% | -55.8% |
| May 27 | Needham | Downgrade | Buy → Hold | — | $6.27 | $2.30 | -63.3% | -62.8% | -60.4% | -58.2% | -60.0% | -55.8% |
| May 16 | Wedbush | Maintains | Outperform → Outperform | — | $6.73 | $6.87 | +2.1% | -3.4% | -4.2% | +1.8% | -2.1% | -2.5% |
| May 16 | Chardan Capital | Maintains | Buy → Buy | — | $6.73 | $6.87 | +2.1% | -3.4% | -4.2% | +1.8% | -2.1% | -2.5% |
| May 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $6.73 | $6.87 | +2.1% | -3.4% | -4.2% | +1.8% | -2.1% | -2.5% |
| May 12 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $6.99 | $7.25 | +3.7% | +0.1% | -5.3% | -13.3% | -3.7% | -7.0% |
| May 12 | Canaccord Genuity | Maintains | Buy → Buy | — | $6.99 | $7.25 | +3.7% | +0.1% | -5.3% | -13.3% | -3.7% | -7.0% |
| May 9 | JP Morgan | Maintains | Overweight → Overweight | — | $7.04 | $7.01 | -0.4% | -0.7% | -0.6% | -6.0% | -13.9% | -4.4% |
| May 9 | Chardan Capital | Maintains | Buy → Buy | — | $7.04 | $7.01 | -0.4% | -0.7% | -0.6% | -6.0% | -13.9% | -4.4% |
| May 9 | Goldman Sachs | Maintains | Neutral → Neutral | — | $7.04 | $7.01 | -0.4% | -0.7% | -0.6% | -6.0% | -13.9% | -4.4% |
| Apr 9 | Needham | Maintains | Buy → Buy | — | $4.79 | $4.61 | -3.8% | +12.7% | +3.1% | +10.0% | +23.4% | +36.3% |
| Mar 3 | Canaccord Genuity | Maintains | Buy → Buy | — | $9.45 | $9.42 | -0.3% | -7.0% | -8.4% | -2.5% | -4.9% | -7.2% |
| Mar 3 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $9.45 | $9.42 | -0.3% | -7.0% | -8.4% | -2.5% | -4.9% | -7.2% |
| Mar 3 | Goldman Sachs | Maintains | Neutral → Neutral | — | $9.45 | $9.42 | -0.3% | -7.0% | -8.4% | -2.5% | -4.9% | -7.2% |
| Feb 28 | Needham | Maintains | Buy → Buy | — | $9.40 | $9.55 | +1.6% | +0.5% | -6.5% | -7.9% | -2.0% | -4.4% |
| Feb 28 | Chardan Capital | Maintains | Buy → Buy | — | $9.40 | $9.55 | +1.6% | +0.5% | -6.5% | -7.9% | -2.0% | -4.4% |
| Feb 28 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $9.40 | $9.55 | +1.6% | +0.5% | -6.5% | -7.9% | -2.0% | -4.4% |
| Nov 19 | Needham | Maintains | Buy → Buy | — | $13.66 | $13.81 | +1.1% | -3.7% | -4.5% | -6.4% | +3.3% | +3.2% |
| Nov 19 | Leerink Partners | Maintains | Outperform → Outperform | — | $13.66 | $13.81 | +1.1% | -3.7% | -4.5% | -6.4% | +3.3% | +3.2% |
| Nov 19 | Canaccord Genuity | Maintains | Buy → Buy | — | $13.66 | $13.81 | +1.1% | -3.7% | -4.5% | -6.4% | +3.3% | +3.2% |
| Nov 19 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $13.66 | $13.81 | +1.1% | -3.7% | -4.5% | -6.4% | +3.3% | +3.2% |
| Nov 18 | Chardan Capital | Maintains | Buy → Buy | — | $13.98 | $14.10 | +0.9% | -2.3% | -5.9% | -6.7% | -8.5% | +0.9% |
| Nov 11 | Chardan Capital | Maintains | Buy → Buy | — | $17.45 | $17.65 | +1.1% | -3.4% | -8.1% | -10.2% | -15.1% | -19.9% |
| Nov 8 | Needham | Maintains | Buy → Buy | — | $17.25 | $17.29 | +0.2% | +1.2% | -2.3% | -7.1% | -9.2% | -14.1% |
| Sep 30 | Canaccord Genuity | Maintains | Buy → Buy | — | $18.46 | $18.22 | -1.3% | +0.1% | -7.3% | -8.1% | -13.0% | -11.1% |
No insider trades available.
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Rocket Pharmaceuticals disclosed material information via press release, likely regarding clinical trial results or pipeline updates that could significantly impact stock valuation and investor expectations for the biotech company's future performance.
Mar 27
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Equity Issuance
Rocket (RCKT) agreed to issue equity to Cantor Fitzgerald, likely diluting existing shareholders but providing capital for growth or debt reduction.
Mar 10
8-K
Rocket Pharmaceuticals, Inc. -- 8-K Filing
Rocket Pharmaceuticals reported 2025 results highlighting progress in its genetic therapy pipeline, particularly in cardiovascular applications with ongoing Danon disease experience and advancement in two additional cardiomyopathy programs.
Feb 26
Data updated apr 26, 2026 10:04pm
· Source: massive.com